CN206566257U - A kind of intravascular stent containing diazoxiide - Google Patents
A kind of intravascular stent containing diazoxiide Download PDFInfo
- Publication number
- CN206566257U CN206566257U CN201621185701.8U CN201621185701U CN206566257U CN 206566257 U CN206566257 U CN 206566257U CN 201621185701 U CN201621185701 U CN 201621185701U CN 206566257 U CN206566257 U CN 206566257U
- Authority
- CN
- China
- Prior art keywords
- layer
- diazoxiide
- intravascular stent
- rack body
- heparin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Materials For Medical Uses (AREA)
Abstract
The utility model is related to cardiac vascular medical equipment technical field, a kind of particularly intravascular stent containing diazoxiide, including rack body；If also including macromolecule poly nitride layer and dried layer diazoxiide layer；The diazoxiide layer is coated on rack body successively with macromolecule poly nitride layer, and macromolecule poly nitride layer is located at outermost layer；The macromolecule poly nitride layer includes chitosan layer, gelatin layer or heparin layer.The technical solution of the utility model can give full play to effect of the diazoxiide to blood vessel, and the support is played a role in intravascular smooth muscle proliferation and promotion rack surface endothelialization is suppressed.
Description
Technical field
The utility model is related to cardiac vascular medical equipment technical field, particularly a kind of blood vessel branch containing diazoxiide
Frame.
Background technology
Coronary atherosclerotic heart disease is that coronary artery occurs atherosclerotic lesion and causes blood vessel
Luminal stenosis or obstruction, cause heart disease caused by myocardial ischemia, anoxic or necrosis, are commonly referred to as " coronary heart disease ".Coronary disease
Disease is to endanger one of severe cardiovascular disease of human health, and percutaneous coronary stent endoprosthesis has become treatment coronary heart disease
Conventional meanses.
Support biotechnology is developed rapidly, the work such as supporting structure, production technology, pharmaceutical carrier and coating medicine
Skill is improved, and improves curative effect of the Stent in clinical Coronary Artery Disease Intervention Treatment.
50% percutaneous coronary plasty is up to compared to restenosis rate, bare mental stents restenosis rate declines to a great extent；But 10% ~
20% in-stent restenosis rate and late period stent thrombosis be still restrict skin coronary stenting after clinical effectiveness it is important
Factor.In-stent restenosis and late period thrombus in stents can cause patient to occur to include angina pectoris, acute myocardial infarction AMI again, even
The Major cardiovascular adverse events such as Sudden Cardiac Death, are the Tough questions that current coronary heart disease intervention support treatment is faced below.
Clinical research discovery stenter to implant patient's generation in-stent restenosis is come from before and after culprit vessel Revascularization
Pathological change, show as Endothelial Dysfunction and endometrial hyperplasia etc..Endothelial Dysfunction postpones endothelialization time-histories；Endometrial hyperplasia
Main component is smooth muscle cell, and early stage membrane processes are formed, blood platelet, the macrophage of aggregation discharge a large amount of cells
The factor, wherein platelet derived growth factor can stimulate the smooth muscle cell in vascular wall middle level to be migrated to inner membrance, breed and secrete
Extracellular matrix, around here still with phenotypic changes of vascular smooth muscle cells, these result in the formation of new intima to cause support
Interior ISR.To overcome in-stent restenosis, scientific research personnel have developed drug-eluting stent in succession, but still have 10% narrow again
Narrow rate.
Diazoxiide (Diazoxide), chemical constitution is as follows,
。
Diazoxiide is KATP channel openers, promotes intracellular outward potassium flow, cell membrane potential hyperpolarization, voltage dependent calcium
Passage is closed, and Ca2+ influx is reduced, and intracellular calcium concentration declines, so as to suppress vessel retraction and vascular remodeling.Disclosed in file 1
The parenteral administering mode of diazoxiide, 1 ~ 3mg/kg of dosage of every 5 ~ 15 minutes single injections is to maximum 150mg/kg, so as to treat height
Blood pressure acute disease；Diazoxiide can be with dosage range oral application daily 600 ~ 800mg, so as to handle refractory hypertension.
KATP passages are widely distributed in vivo, vdiverse in function, participate in reconciling insulin secretion, resist myocardial ischemia to protect and make
With, regulation antiotasis etc., KATP passages are the important sensors of coupled cell film potential and cellular energy metabolism state.In the heart
In terms of vascular diseases, KATP passages regulation endothelial cell, smooth muscle cell and vascular function, research have proven to activate endothelial cell
KATP passages have protection endothelial cell, the effect for correcting Endothelial Dysfunction and suppress the effect such as late period endometrial hyperplasia.
Compared with existing medicament intravascular stent, diazoxiide can improve inner skin cell function by activating KATP passages,
Promote implantation rack surface endothelialization；Suppress vascular smooth muscle cell proliferation and smooth muscle Phenotypic change, be potential anti-angiogenic propagation
Medicine, prevent with reverse vascular smooth muscle Phenotypic change with increment in have very important effect.But how should by diazoxiide
It is then a technical problem for being badly in need of solving on intravascular stent.
File 1：100 μm of ol/L diazoxiide hypoxia-reoxygenation Microvascular Endothelial Cellss are played protective effect (Zhang Yonghua,
Chen Qiuping, Cao Su, Shen Shiren, Chinese Tissue Engineering Study, 2012,16 (28):5149-5153).
Utility model content
Preferably it is applied in order that obtaining diazoxiide on intravascular stent, the utility model provides a kind of blood vessel containing diazoxiide
Support.
To achieve the above object, a kind of intravascular stent containing diazoxiide, including support sheet are provided according to the utility model
Body；If also including macromolecule poly nitride layer and dried layer diazoxiide layer；The diazoxiide layer is coated successively with macromolecule poly nitride layer
In on rack body, and macromolecule poly nitride layer is located at outermost layer；The macromolecule poly nitride layer includes chitosan layer, gelatin
Layer or heparin layer.
As the improved technical scheme of the utility model, number is 10 ~ 12 layers to the diazoxiide layer by layer.
As the improved technical scheme of the utility model, number is 11 layers to the diazoxiide layer by layer.
It is used as the improved technical scheme of the utility model, in addition to polymer base coat；The polymer base coat is located at phenodiazine
Between piperazine layer and rack body, including chitosan layer or heparin layer.
As the improved technical scheme of the utility model, in addition to layer is plugged, the layer that plugs is located at rack body and two
Between nitrogen piperazine layer and between diazoxiide layer and diazoxiide layer；It is described plug layer for chitosan layer, heparin layer in one kind or
Two kinds.
As the improved technical scheme of the utility model, the material of the rack body is titanium alloy, stainless steel or platinum-iridium
Alloy.
The utility model has the advantages that
Diazoxiide layer is coated with the intravascular stent that the utility model is provided, is applied to by such intravascular stent in blood vessel
When, the intravascular stent can selectively improve blood vessel inner skin cell function, suppress intravascular smooth muscle cell proliferation；It is coated on simultaneously
Macromolecule polymer on diazoxiide layer can play a part of sustained release to the medicine, release medicine of the extending bracket in human body
Action time.
Brief description of the drawings
A kind of schematic perspective view of the intravascular stent containing diazoxiide of the present utility model of accompanying drawing 1；
A kind of a kind of structural representation at A of the intravascular stent containing diazoxiide of the present utility model of accompanying drawing 2；
A kind of second of structural representation at A of the intravascular stent containing diazoxiide of the present utility model of accompanying drawing 3；
A kind of structural representation of the third at A of the intravascular stent containing diazoxiide of the present utility model of accompanying drawing 4；
In figure：1st, rack body；2nd, diazoxiide layer；3rd, macromolecule poly nitride layer；41st, chitosan layer；42nd, heparin layer.
Specific implementation method
The preparation method of diazoxiide and intravascular stent illustrated below, when the intravascular stent that utility model is provided is not limited to
This.
The utility model provides a kind of intravascular intravascular stent, and the intravascular stent includes at least one layer of diazoxiide.Phenodiazine
Piperazine can be, but not limited to routinely compound synthesis method and be made.
The diazoxiide layer of the application can be used individually or with other therapeutic combinations, such as steroids（Include, but not limited to ground
Sai meter Song, hydrocortisone, prednisone, percorten）Deng.The coating that the utility model is provided can use routine side
Method is coated on intravascular stent body, such as can be using coating self assembly, immersion seasoning, multilayer construction from part etc..
A kind of intravascular stent containing diazoxiide, including rack body；If also including macromolecule poly nitride layer and dried layer phenodiazine
Piperazine layer；The diazoxiide layer is coated on rack body successively with macromolecule poly nitride layer；The macromolecule poly nitride layer includes
Chitosan layer, gelatin layer or heparin layer；Number is 10 ~ 12 layers more preferably 11 layers to the diazoxiide layer by layer；Further have and also wrap
Include polymer base coat；The polymer base coat is between diazoxiide layer and rack body, including chitosan layer or heparin layer；Also
Including plugging layer, the layer that plugs is located between rack body and macromolecule poly nitride layer, and by adjacent diazoxiide layer and two
Nitrogen piperazine interlayer is separated；The layer that plugs is the one or two kinds of in chitosan layer, heparin layer；The rack body is titanium alloy
Support, titanium framework, stainless steel stent or platinum-iridium alloy.
The stereochemical structure for the coating bracket that the utility model is provided is as shown in Figure 1.The intravascular stent include rack body and
It is coated on diazoxiide layer and macromolecule poly nitride layer, such as Fig. 2., can selectivity after stent with coating in blood vessel Surface coating diazoxiide
Suppress vascular smooth muscle hyperplasia, it is to avoid the generation of postoperative restenosis.The support top layer macromolecule that many poly layer of macromolecule can be commonly used
Poly nitride layer, preferably shell poly layer, heparin layer, more preferably heparin layer.Heparin layer can be liquaemin or low molecular sodium heparin
Layer.Multiple specific materials are after rack surface formation single coating, and macromolecule poly nitride layer can be made up of multilayer single coating.
It is preferred that also include insert layer, insert layer be located between intravascular stent and macromolecule poly nitride layer, in the present embodiment
In, insert layer is made up of chitosan layer with heparin layer, and insert layer separates adjacent diazoxiide layer with diazoxiide interlayer, is plugging
Layer in outermost layer after the completion of diazoxiide layer arrangement with coating macromolecule poly nitride layer, as shown in Figure 3.Using the intravascular of the structure
Support can be such that medicine is discharged after intravasation, the extended treatment time, promote post-surgical vascular to recover.Macromolecule poly nitride layer is preferred
Heparin layer.During using heparin layer as macromolecule poly nitride layer, gained coating bracket surface is more smooth, is easy to climbing for endothelial cell
It is attached, be conducive to medicine in bracket coating to enter cells play curative effect.
There is polymer base coat and plug the intravascular stent of layer, structure in the present embodiment is as shown in figure 4, intravascular stent bag
Include rack body and the second construction unit.Second construction unit is sequentially stacked heparin layer, first layer diazoxiide layer, chitosan layer
（Plug layer）, second layer diazoxiide layer, repeat the unit 10 times, wherein, it is polymerization to be attached at rack body last layer heparin layer
Thing bottom, obtains intravascular stent.
The preparation method of the intravascular stent of diazoxiide coating illustrated below, the intravascular stent provided when the utility model
Not limited to this.
Embodiment 1 illustrates multilayer construction from part and prepares cladding stent with coating in blood vessel preparation method.
Take in the NaOH solution that domestic Pt-Ir alloy bracket is immersed in 60 DEG C, concentration is 20% and soak 24 hours, it is fully clear
Wash, then clean with distilled water ultrasonic cleaning, drying at room temperature.
Diazoxiide ethanol solution preparation method：Diazoxiide is added in ethanol solution and is configured to 100 μm of ol/L of concentration, is prepared
Into being used as diazoxiide ethanol solution.
Taking heparin sodium is dissolved in distilled water, is prepared into PH=4, mass concentration 5g/L polyanion solution.Chitosan is molten
Solution is prepared into PH=4, mass concentration 5g/L said polycation solution in the acetum of volume fraction 1%.
The alloy bare bracket for soaking peroxide sodium hydroxide solution is immersed in diazoxiide solution and heparin solution successively respectively
In, soak time is respectively 1,15 minutes, and the support of coating is dried after terminating for immersion every time；In this, as one
Individual unit, repeatedly the unit, repeats 10 units, obtains the support of the composite coating containing diazoxiide；Support
Coating is that, with heparin layer to plug layer, one layer of heparin layer is located at rack body and is located at two with diazoxiide layer support, remaining heparin layer
Between nitrogen piperazine layer and diazoxiide layer, chitosan layer is the bracket coating of macromolecule poly nitride layer.
Embodiment 2 illustrates multilayer construction from part and prepares cladding stent with coating in blood vessel preparation method.
Take in the NaOH solution that domestic stainless steel stent is immersed in 60 DEG C, concentration is 20% and soak 24 hours, fully cleaning,
Ultrasonic cleaning, drying at room temperature are cleaned with distilled water again.
Diazoxiide ethanol solution preparation method：Diazoxiide is added in ethanol solution and is configured to 100 μm of ol/L of concentration, is prepared
Into being used as diazoxiide ethanol solution.
Taking heparin sodium is dissolved in distilled water, is prepared into PH=4, mass concentration 5g/L polyanion solution.
In the acetum for dissolving the chitosan in volume fraction 1%, be prepared into PH=4, mass concentration 5g/L poly- sun from
Sub- solution.
The alloy bare bracket for soaking peroxide sodium hydroxide solution is immersed in chitosan solution successively respectively, heparin solution,
Diazoxiide solution ethanol solution, soak time is respectively 15,15,1 minutes, the support after immersion terminates every time to coating
It is dried；In this, as a unit, repeat the unit 10 times, chitosan layer and heparin layer are to plug layer here,
Finally gained support is immersed liquaemin layer is obtained in heparin sodium aqua as high polymer layer, obtain answering containing diazoxiide
It is, collectively as layer is plugged, to plug layer located at rack body with chitosan layer, heparin layer to close the coating on the support of coating, support
Between diazoxiide layer and between diazoxiide layer and diazoxiide layer, outermost layer heparin layer is macromolecule poly nitride layer.
Embodiment 3 illustrates multilayer construction from part and prepares cladding stent with coating in blood vessel preparation method.
Domestic titanium alloy support is taken to be immersed in 60oC, concentration is soak 24 hours in 20% NaOH solution, fully cleaning,
Ultrasonic cleaning, drying at room temperature are cleaned with distilled water again.
Diazoxiide ethanol solution preparation method：Diazoxiide is added in ethanol solution and is configured to 100 μm of ol/L of concentration, is prepared
Into being used as diazoxiide ethanol solution.
Taking heparin sodium is dissolved in distilled water, is prepared into PH=4, mass concentration 5g/L polyanion solution.Chitosan is molten
Solution is prepared into PH=4, mass concentration 5g/L said polycation solution in the acetum of volume fraction 1%.
The alloy bare bracket for soaking peroxide sodium hydroxide solution is immersed in heparin solution, diazoxiide solution second successively respectively
In alcoholic solution, chitosan solution, and diazoxiide solution, soak time is respectively 15,1,15,1 minute, after immersion terminates every time
The support of coating is dried；In this, as a unit, repeatedly the unit, repeats 10 units.
Finally gained support is immersed in chitosan solution and obtains chitosan layer as high polymer layer, the blood containing diazoxiide is obtained
Pipe holder；What is plugged between rack body and diazoxiide layer plugs liver to replace between heparin layer, diazoxiide layer and diazoxiide layer
Plain layer, chitosan layer, chitosan layer are outermost layer macromolecule poly nitride layer.
It the foregoing is only of the present utility model to be preferable to carry out, be not limited to the utility model, for ability
For the technical staff in domain, the utility model can have various modifications and variations.It is all it is of the present utility model spirit and principle it
Interior, any modification of gained, improvement, replacement etc. should be included within protection domain of the present utility model.
Claims (6)
1. a kind of intravascular stent containing diazoxiide, including rack body；If characterized in that, also include macromolecule poly nitride layer with
Dried layer diazoxiide layer；The diazoxiide layer is coated on rack body successively with macromolecule poly nitride layer, and macromolecule poly
Nitride layer is located at outermost layer；The macromolecule poly nitride layer includes chitosan layer, gelatin layer or heparin layer.
2. a kind of intravascular stent containing diazoxiide according to claim 1, it is characterised in that number is the diazoxiide layer by layer
10 ~ 12 layers.
3. a kind of intravascular stent containing diazoxiide according to claim 1, it is characterised in that number is the diazoxiide layer by layer
11 layers.
4. a kind of intravascular stent containing diazoxiide according to claim 1, it is characterised in that also including polymer base coat；
The polymer base coat is between diazoxiide layer and rack body, including chitosan layer or heparin layer.
5. a kind of intravascular stent containing diazoxiide according to claim 1, it is characterised in that described also including plugging layer
Layer is plugged between rack body and diazoxiide layer and between diazoxiide layer and diazoxiide layer；The layer that plugs gathers for shell
One or two kinds of in sugar layer, heparin layer.
6. a kind of intravascular stent containing diazoxiide according to claim 1, it is characterised in that the material of the rack body
For titanium alloy, stainless steel or platinum-iridium alloy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201621185701.8U CN206566257U (en) | 2016-11-04 | 2016-11-04 | A kind of intravascular stent containing diazoxiide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201621185701.8U CN206566257U (en) | 2016-11-04 | 2016-11-04 | A kind of intravascular stent containing diazoxiide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN206566257U true CN206566257U (en) | 2017-10-20 |
Family
ID=60062287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201621185701.8U Active CN206566257U (en) | 2016-11-04 | 2016-11-04 | A kind of intravascular stent containing diazoxiide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN206566257U (en) |
-
2016
- 2016-11-04 CN CN201621185701.8U patent/CN206566257U/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101199873B (en) | Medicament elution instrument nanometer class colon washer machineole drug releasing structure and preparing method thereof | |
| JP2017002083A5 (en) | ||
| JP2008520748A5 (en) | ||
| CN104888282B (en) | A kind of degradable zinc-base micropore carried stent and preparation method thereof | |
| EP1441749A2 (en) | Vascular stent or graft coated or impregnated with protein tyrosine kinase inhibitors and method of using same | |
| CN101474455A (en) | Nano micropore structure capable of storing and releasing various kinds of medicament for medicament eluting instrument and preparation method | |
| JP2014530058A (en) | Intervention medical device and manufacturing method thereof | |
| CN206566257U (en) | A kind of intravascular stent containing diazoxiide | |
| CN201179222Y (en) | Medicament coating bracket | |
| Ural et al. | Coronary embolism complicating aortic valve endocarditis: treatment with successful coronary angioplasty | |
| CN202146455U (en) | Cardiovascular composite medicine bracket | |
| WO2018059207A1 (en) | New use of amlexanox | |
| CN205698633U (en) | A kind of bracket for eluting medicament | |
| CN103372234B (en) | Drug eluting stent and preparation method thereof | |
| CN108354698A (en) | A kind of magnesium alloy biliary tract rack and preparation method thereof | |
| CN202740163U (en) | Cardiovascular medicament coating rack | |
| WO2018232772A1 (en) | Degradable and withdrawable 4d printing linear organic human body stent and using method therefor | |
| CN107865983B (en) | Medicine stent and preparation method thereof | |
| CN205924551U (en) | Contain 2 vascular undercoating support on amino ethyl ester diphenyl boric acid layer | |
| CN203915574U (en) | Containing composite coating support in the blood vessel of Thalidomide layer | |
| CN103083323A (en) | Application of fasudil hydrochloride in preparation of medicament for promoting in-vivo survival and repair of mesenchymal stem cells and preparation of fasudil hydrochloride | |
| Quan et al. | Acute left heart failure caused by Takayasu arteritis: a case report and literature review | |
| CN216221894U (en) | Novel esophageal mitomycin drug eluting stent | |
| CN209645151U (en) | A kind of recoverable support for Coronary Artery Disease Intervention Treatment | |
| CN213374133U (en) | Cardiovascular medicine coating stent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |